Oncology

Oncology is still an area with large medical needs and the general aging of the population means that morbidity and mortality figures are expected to rise over the next few years. Each year, 6.5 million people are diagnosed with cancer and over 4 million people die worldwide as a result.¹ This includes a large number of young people who suffer from severe forms of cancer, including leukemia, ovarian cancer, glioblastoma and breast cancer.

Five pharmaceutical development projects in the Karolinska Development portfolio focus on innovative therapies for the treatment of cancer. Each of these projects is estimated to have unique, promising treatment goals and four of the projects are in clinical development phases.

Concept Development

Lead Discovery

Lead Optimization

Preclinical Development

Phase I

Phase II

Phase III

Launch

Axelar AB

KDev Oncology AB (AKN-028)

Aprea AB

Oncopeptides AB

KDev Oncology AB (GliGene)

Aprea AB Aprea is developing pharmaceuticals that reactivate the p53 protein, which is damaged in many types of cancer. www.aprea.com		Axelar AB Axelar is developing a cancer drug that inhibits the Insulin-like Growth Factor 1 receptor (IGF-1). www.axelar.se		KDev Oncology AB Akinion Pharmaceuticals is developing FLT-3 kinase inhibitors for cancer treatment. www.akinion.com
Oncopeptides AB Oncopeptides has developed a series of patented oligopeptides for cancer treatment. www.oncopeptides.se		KDev Oncology AB GliGene is developing antagonists to the Hedgehog pathway for the treatment of solid tumors.

¹⁾Source:^{????????????????}WHO, International Agency for Research on Cancer, Globocan, 2008, http://globocan.iarc.fr